Business
Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering
Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n\n\n\nTetra Bio-Pharma Inc. Announces Termination of \"At-The-Market\" Offering\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTetra Bio-Pharma Inc. Announces Termination of \"At-The-Market\" Offering\nCanada NewsWire\nOTTAWA, ON, Nov. 4, 2021\n\n\n\nOTTAWA, ON, Nov. 4, 2021 /CNW/ - Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Company\") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, announced today the termination of its previously announced \"at-the-market\" equity offering program (the \"ATM Program\") with Canaccord Genuity Corp. as sole agent.\n\n \n \n \n \n \n \n\n \nThe termination of the ATM Program is effective as of November 11, 2021. Tetra will not be using the ATM Program. The ATM Program was established on May 28, 2021, allowing the Company to issue and sell up to $10 million aggregate amount of common shares of the Company to the public from time to time, at the Company's discretion. As of the date of this announcement, Tetra had not sold any of its common shares under the ATM Program. \nAbout Tetra Bio-Pharma\nTetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.\nFor more information visit: www.tetrabiopharma.com\nNeither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.\nForward-looking statementsSome statements in this rele...